Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM)…
<!-- Name:DistributionId Value:8846053 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Chimerix
Plasma Cell Leukemia Market is Expected to Showcase Significant Growth, Predicts…
<!-- Name:DistributionId Value:8831879 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:True -->…
Chimerix Announces Presentation of Multiple Imipridone Datasets at American…
<!-- Name:DistributionId Value:8810512 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen…
<!-- Name:DistributionId Value:8800500 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties - DURHAM, N.C., Sept. 26, 2022 (GLOBE NEWSWIRE) --…
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years – - Emergent BioSolutions, Inc. Payment Increases to $238M…
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with…
DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives…
Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in…
DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives…
Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference
DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives…
Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline…
– Plenary Session Presentation on Saturday, November 20 – – Company to Host Conference Call at 8:30 a.m. ET on Monday, November 22 – DURHAM, N.C., Nov. 19, 2021 (GLOBE NEWSWIRE) --…